Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2015517 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTPOLBKMT2AMTOR | |
| SCHEMBL23976543 | 0.67 | GAA (0.67) | SMN1; SMN2GAAPOLBCYP1A2HSD17B10 | |
| SCHEMBL13270199 | 0.67 | HTT (0.53) | SMN1; SMN2GAAMAPTPOLBHTT | |
| SCHEMBL626827 | 0.67 | GAA (0.76) | SMN1; SMN2GAAPOLBCYP1A2HSD17B10 | |
| SCHEMBL30071250 | 0.67 | GAA (0.76) | SMN1; SMN2GAAPOLBCYP1A2HSD17B10 | |
| Bromide SCHEMBL11500766 | 0.66 | GAA (0.73) | SMN1; SMN2GAAPOLBCYP1A2HSD17B10 | |
| SCHEMBL6245092 | 0.65 | GAA (1.00) | SMN1; SMN2GAAPOLBCYP1A2HSD17B10 | |
| SCHEMBL27508818 | 0.64 | HPGD (0.63) | SMN1; SMN2GAAMAPTPOLBHTT | |
| SCHEMBL2562391 | 0.64 | GAA (0.71) | SMN1; SMN2GAAPOLBCYP1A2HSD17B10 | |
| SCHEMBL20220978 | 0.64 | GAA (0.71) | SMN1; SMN2GAAPOLBCYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513069-B1 | ANTIFUNGAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-10-15 | — | — | EP | claimed |
| EP-2513069-A1 | ANTIFUNGAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-24 | — | — | EP | claimed |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-10-04 | — | — | US | claimed |
| WO-2011072345-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-23 | — | — | WO | claimed |
| EP-2513069-B1 | ANTIFUNGAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2513069-A1 | ANTIFUNGAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011072345-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | ERG28, DPM1, CYP51A1 | SMN1; SMN2 4701/4885GAA 19/4885MAPT 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.